证券日报网讯 12月28日，申联生物发布公告称，童光志因个人原因申请辞去公司董事职务，同时一并 辞去在公司董事会下设的战略委员会、提名委员会中担任的委员职务，辞任后不在公司担任何职务；聂 文豪因工作调整申请辞去公司副总经理职务，辞任后仍在公司担任董事一职，并在公司及子公司担任其 他职务。2025年12月25日，公司召开职工代表大会，选举张震为公司第四届董事会职工代表董事。公司 第四届董事会第六次会议选举职工代表董事张震先生为公司第四届董事会提名委员会委员和第四届董事 会战略委员会委员。 （编辑 王江浩） ...

（文章来源：证券日报） 证券日报网讯 12月28日，申联生物发布公告称，公司拟续聘容诚会计师事务所（特殊普通合伙）为 2025年度财务报告及内控审计机构，聘期一年，审计费用57万元，其中财务报告审计费45万元，较上年 度下降6.25%，内控审计费12万元不变，该议案已获董事会通过，尚待股东会审议。 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-044 申联生物医药（上海）股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 12 月 27 日召开第四届董事会第六次会议，审议通过了《关 于续聘会计师事务所的议案》，公司拟续聘容诚会计师事务所（特殊普通合伙） （以下简称"容诚会计师事务所"）为公司 2025 年度财务报告和内部控制审计机 构，聘期一年。现将相关事项公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 截至2024年12月31日，容诚会计师事务所共有合伙人196人，共有注册会计 师1549人，其中781人签署过证券服务业务审计报告。 3、业务规模 1、基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于1988年8月，2013年12月10日改制为特殊普通合伙 企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证券服 务业务。注册地址为北京市西城 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会于近日收到公司董事童光志先生、副总经理聂文豪先生递交 的书面辞职报告。童光志先生因个人原因申请辞去公司董事职务，同时一并辞去 在公司董事会下设的战略委员会、提名委员会中担任的委员职务，辞任后不在公 司担任何职务；聂文豪先生因工作调整申请辞去公司副总经理职务，辞任后仍在 公司担任董事一职，并在公司及子公司担任其他职务。根据《中华人民共和国公 司法》（以下简称"《公司法》"）《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》"）等法律法规及《申联生物医药（上海）股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，童光志先生和聂文豪先生的 辞职报告自送达董事会之日起生效。 证券代码：688098 证券简称：申联生物 公告编号：2025-045 申联生物医药（上海）股份有限公司 关于公司董事、高级管理人员离任暨选举职工代表董 事、补选董事会专门委员会委员的公告 二、职工代表董事选举情况 根据《公司法》《上海证券交易所上市公司自律监管指引第 1 ...

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Group 1 - China Shenhua plans to issue A-shares and pay cash to acquire assets from its controlling shareholder, China Energy Group, and its wholly-owned subsidiary, West Energy, for a total transaction price of 133.598 billion yuan, with 30% paid in shares and 70% in cash [1][4] - Qingdao Port intends to invest approximately 15.7 billion yuan in two terminal projects [4] - Jifeng Co., Ltd. has been awarded a total assembly project for passenger car seats, with an estimated total lifecycle value of 9.8 billion yuan [4] Group 2 - Shengxin Lithium Energy's partner, Zhongxin Aviation, plans to purchase 200,000 tons of lithium salt products from the company between 2026 and 2030 [4] - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in an advanced materials supporting waste salt comprehensive utilization project [4] - Tianqi Lithium's third-phase chemical-grade lithium concentrate expansion project has been completed and is now in trial operation [4] Group 3 - Oriental Cable has recently won projects totaling approximately 3.125 billion yuan [4] - Jiangshan Luneng has signed a series of contracts totaling approximately 815 million yuan [4] - Huahai Wenkang has produced over 800 CMP equipment units [4] Group 4 - Sichuan Chengyu's subsidiary plans to acquire 85% of Jingyi Company for 2.409 billion yuan [4] - Qi Yi Er intends to acquire 60% of Fangzhou Technology through acquisition and capital increase [4] - Tianchuang Fashion is planning a change of control, resulting in a stock suspension [4]

据天眼查APP显示，申联生物医药(上海)股份有限公司成立于2001年06月28日，注册资本41064.4万人民 币。（数据宝） 12月19日申联生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | | | | | 中信建投证券股份有 | 国信证券股份有限公司上海 | | 205.30 | 1806.64 | 8.80 | -2.33 | 限公司广西分公司 | 陆家嘴环路证券营业部 | （文章来源：证券时报网） 申联生物12月19日大宗交易平台出现一笔成交，成交量205.30万股，成交金额1806.64万元，大宗交易成 交价为8.80元，相对今日收盘价折价2.33%。该笔交易的买方营业部为中信建投证券股份有限公司广西 分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。 证券时报·数据宝统计显示，申联生物今日收盘价为9.01元，上涨2.15%，日换手率为0.63 ...

Core Viewpoint - The company Shenyuan Biotech (688098.SH) announced that its affiliate Yangzhou Shizhi Source Biotechnology Co., Ltd. has received a patent from the National Intellectual Property Administration for a novel treatment method for HIV infection using monoclonal antibodies targeting CD4 [1] Group 1: Patent and Technology - The patent pertains to a method for treating and functionally curing HIV infection through monoclonal antibodies that target CD4, including their compositions and usage [1] - The drug UB-421, under development by Shizhi Source, has a unique mechanism of action that effectively blocks HIV from entering host cells by competitively binding to the CD4 receptor on T cells [1] Group 2: Market Implications - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing HIV treatments, as it does not directly target viral genes [1] - The drug will primarily focus on areas such as multi-drug resistance and functional cure in the domestic market [1]

Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), has recently obtained a patent from the National Intellectual Property Administration for an invention related to the treatment and functional cure of HIV infection using monoclonal antibodies targeting CD4 [1] Group 1 - The patent covers a method for preventing, treating, and functionally curing HIV infection through monoclonal antibodies and their compositions [1] - The drug UB-421, which is in the research pipeline for AIDS treatment, has a novel mechanism of action by competitively inhibiting HIV entry into host cells through binding to the CD4 receptor on T cells [1] - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing AIDS treatments, as it does not directly target viral genes and also possesses immunomodulatory effects [1] Group 2 - The research on UB-421 will primarily focus on areas such as multidrug resistance and functional cure in the domestic market [1]

格隆汇12月19日丨申联生物(688098.SH)公布，公司联营公司扬州世之源生物科技有限责任公司（简 称"世之源"）于近日获得国家知识产权局颁发的"藉由针对CD4之单克隆抗体介导竞争型HIV进入抑制之 HIV感染的治疗和功能性治愈"的发明专利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使 用此组合物以预防、治疗和功能性治愈HIV感染的方法。 本次获得发明专利是公司及世之源重视创新药研发及知识产权布局的成果，为UB-421在多重耐药适应 症的临床推进及开展艾滋病功能性治愈等研究提供了核心技术保护。本次获得发明专利短期内不会对公 司经营业绩产生重大影响，但有利于公司及世之源发挥自主知识产权的技术优势，促进技术创新，进一 步增强公司在创新药领域的布局和核心竞争力。 世之源在研管线艾滋病治疗单克隆抗体药物UB-421具有全新的作用机制，该药物通过与靶向T细胞表面 的CD4受体结构域1结合，以竞争性抑制的方式有效阻断HIV病毒进入宿主细胞。因UB-421并非直接针 对病毒基因，所以相较于当前市场上现有的治疗艾滋病药物，UB-421引起病毒耐药突变的概率较低， 且具有免疫调节作用。UB-421在国内将主要针对多 ...